Leaflet SUGAMMADEX APTAPHARMA 100mg / ml solution for injection


Indicated for: reversal of neuromuscular blockade

Route of administration: injectable

Substance: sugamadex (neuromuscular blocker)

ATC: V03AB35 (Various | All other therapeutic products | Antidotes)

Sugammadex is a reversal agent used to counteract the effects of neuromuscular blockers such as rocuronium and vecuronium after surgical procedures. It works by directly binding to the neuromuscular blocking agents, facilitating the recovery of muscle function.

The medication is administered intravenously, as directed by a doctor, usually at the end of surgery. It is important for administration to be performed under medical supervision.

Patients should be aware of potential side effects, such as nausea, hypotension, or allergic reactions. It is important to inform the doctor of any unusual symptoms.

Common side effects include nausea, hypotension, and headache. In rare cases, severe reactions such as anaphylactic reactions may occur. Patients should be informed of these risks before administration.

General data about SUGAMMADEX APTAPHARMA 100mg / ml

  • Substance: sugamadex
  • Date of last drug list: 01-12-2023
  • Commercial code: W69836001
  • Concentration: 100mg / ml
  • Pharmaceutical form: solution for injection
  • Quantity: 10
  • Product type: generic
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: LABORATORIOS NORMON, S.A. - SPANIA
  • Holder: APTA MEDICA INTERNACIONAL D.O.O. - SLOVENIA
  • Number: 15158/2023/01
  • Shelf life: 18 months-after packing for marketing;after the first opening of the bottle- it is used immediately

Pharmaceutical forms available for sugamadex

Concentrations available for sugamadex

  • 100mg/ml
  • 10mg/ml
  • 50mg/ml